arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

NEXGEL, INC.

NXGL
$3.85 ▼ -0.16 (-3.99%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
9 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

NEXGEL, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $30.2M
Dividend Yield —
Revenue Growth 31.5% ↘
Op. Margin -29.3% ↗
ROIC -52.5% ↘
FCF / Share $-0.18 ↗
Trailing P/E —
Price / Book 7.0x
FCF Yield —
Debt / Equity 0.13
info Valuation on last close. End-of-day price, Nov 5, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.42M
↑ +31.5% —
Net Income Profit after all expenses
$-3.00M
↑ +8.6% —
Operating Margin Operating profit as % of sales
-29.3%
↑ +28.3% 8th
FCF / Share Free cash flow per share
$-0.18
↑ +73.5% —
Long-Term Debt Long-term obligations
$588.00K
↓ -14.2% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
9
Returns ↓
13
Financial Health ↓
78
Cash Quality ↓
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 35 quarters